

Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Ronald Bukowski, M.D.

Committee: Oncologic Drugs Advisory Committee Meeting (ODAC)

Meeting Date: September 19, 2017

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item: the committee will discuss supplemental new drug application (sNDA) 021938/033 SUTENT (sunitinib malate) oral capsules, submitted by C.P. Pharmaceuticals International C.V., represented by Pfizer, Inc. (authorized U.S. agent). The proposed indication (use) for this product is for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy. The topic of this meeting is a particular matter involving specific parties.

I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
Investment	PHSTX JFNAX FBTAX FBDIX Healthcare Sector Funds	current aggregate value of the health sector funds \$150,000 – 200,000
Chair of the Data Monitoring Committee	Bristol Myers Squibb (Competing Firm)	\$0 – 5,000 total

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/S/
Signature

September 5, 2017
Date